Abstract

Sickle cell disease (SCD) is an umbrella term for a group of life-long debilitating autosomal recessive disorders that are caused by a single-point mutation (Glu→Val) that results in polymerization of hemoglobin (Hb) and reversible sickle-shape deformation of erythrocytes. This leads to increased hemolysis of erythrocytes and microvascular occlusion, ischemia-reperfusion injury, and tissue infarction, ultimately causing multisystem end-organ complications. Sickle cell anemia (HbSS) is the most common and most severe genotype of SCD, followed by HbSC, HbS thalassemia, HbS+thalassemia, and rare and benign genotypes. Clinical manifestations of SCD occur early in life, are variable, and are modified by several genetic and environmental factors. Nearly 500 children with SCD continue to die prematurely every day, due to delayed diagnosis and/or lack of access to comprehensive care in sub-Saharan Africa (SSA), a trend that needs to be urgently reversed. Despite proven efficacy in developed countries, newborn screening programs are not universal in SSA. This calls for a consolidated effort to make this possible, through the use of rapid, accurate, and cheap point-of-care test kits which require minimal training. For almost two decades, hydroxyurea (hydroxycarbamide), a century-old drug, was the only disease-modifying therapy approved by the U.S. Food and Drug Administration. Recently, the list expanded to L-glutamine, crizanlizumab, and voxelotor, with several promising novel therapies in the pipeline. Despite its several limitations, hematopoietic stem cell transplant (HSCT) remains the only curative intervention for SCD. Meanwhile, recent advances in gene therapy trials offer a glimpse of hope for the near future, although its use maybe limited to developed countries for several decades.

MeSH

Thalassemia, Adolescent, Erythrocytes, Developed Countries, Anemia, Sickle Cell, Child, Genotype, Public Health, Glutamine, Cells, Therapeutics, Microscopy, Electron, Scanning Transmission, Genes, Reperfusion Injury, Point-Of-Care Systems, Point-Of-Care Testing

Cited by

• Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke. Cureus, 2023
• Feasibility analysis of the SICKLECHECK™ test kit for rapid screening of sickle cell disease at a County Referral Hospital in Kenya. Afr J Lab Med, 2025
• Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. Ann Med Surg (Lond), 2025
• Thalassemia in Sub-Saharan Africa: epidemiology, diagnosis, and management - a narrative review. Ann Med Surg (Lond), 2025
• Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions. Nutrients, 2024
• Burden of vaso-occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients. Br J Haematol, 2025
• Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. Ann Med Surg (Lond), 2024
• Cascade testing effectively identifies undiagnosed sickle cell disease in The Gambia: a quality improvement project. Arch Dis Child, 2025
• Primary Stroke Screening and Hydroxyurea Treatment for Sickle Cell Anemia in Pediatric Healthcare Settings in East and Central Africa: A Narrative Review of Capacity Gaps and Opportunities. Public Health Rev, 2025